Kura Oncology, Inc. (KURA)
NASDAQ: KURA · Real-Time Price · USD
10.08
+0.65 (6.89%)
At close: Oct 8, 2025, 4:00 PM EDT
10.15
+0.07 (0.69%)
After-hours: Oct 8, 2025, 7:58 PM EDT
Kura Oncology Employees
Kura Oncology had 192 employees as of December 31, 2024. The number of employees increased by 50 or 35.21% compared to the previous year.
Employees
192
Change (1Y)
50
Growth (1Y)
35.21%
Revenue / Employee
$433,745
Profits / Employee
-$1,026,938
Market Cap
874.92M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 192 | 50 | 35.21% |
| Dec 31, 2023 | 142 | 9 | 6.77% |
| Dec 31, 2022 | 133 | 12 | 9.92% |
| Dec 31, 2021 | 121 | 32 | 35.96% |
| Dec 31, 2020 | 89 | 29 | 48.33% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
KURA News
- 5 days ago - Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 days ago - Kura Oncology, Inc. (KURA) Presents at UBS Virtual Oncology Day Transcript - Seeking Alpha
- 7 days ago - Kura Oncology and Kyowa Kirin Launch Clinical Trial Evaluating Dual Inhibition of NPM1 and FLT3 Mutations in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) - GlobeNewsWire
- 9 days ago - Kura Oncology and Kyowa Kirin Announce First Patient Dosed in Pivotal Phase 3 KOMET-017 Trial of Ziftomenib for Frontline Acute Myeloid Leukemia (AML) - GlobeNewsWire
- 13 days ago - Kura Oncology and Kyowa Kirin Announce Publication of Pivotal Ziftomenib Data in Relapsed/Refractory NPM1-Mutated AML in the Journal of Clinical Oncology - GlobeNewsWire
- 14 days ago - Kura Oncology to Participate in Upcoming Investor Conference - GlobeNewsWire
- 19 days ago - Kura Oncology Transitioning To Commercial Stage: Why I Choose To Buy - Seeking Alpha
- 22 days ago - Kura Oncology, Inc. - Special Call - Seeking Alpha